With child growth being multifactorial and the glucocorticoids (GC) having many target physiological and biochemical mechanisms, growth and the GC collide in several meeting points. Indirectly, GC have a general anti-anabolic and catabolic influences that include bone, cartilage and muscle proteins. The GC interfere with the GH–IGF-1 axis at the hypothalamic, pituitary and target organ levels, affecting hormone release, receptor abundance, signal transduction, gene transcription, pre-mRNA splicing and mRNA translation. GC disturb normal calcium balance at the intestine and kidney. Direct effects at the growth plate include the suppression of multiple gene expression, chondrocyte proliferation and matrix proteoglycan synthesis, sulfation, release and mineralization as well as the augmentation of hypertrophic cell apoptosis. At the tissues adjacent to the growth plate, GC enhance osteoclast and suppress osteoblast recruitment and function, they reduce muscle strength and disrupt the normal control of vascular invasion at the cartilage–bone interface. Growth damage from GC is maximal during the initial months of treatment and prevention is more effective than post-factual therapy. To reduce these growth-retarding effects, the following measures, which are partly experimental, may be effective in a decreasing order: minimize GC dose and use an alternate-day treatment; utilize the oxazoline analog of prednisolone deflazacort, normalize calcium balance; employ hGH or IGF-1.

1.
Veldhuis JD, Lizarralde G, Iranmanesh A: Divergent effects of short-term glucocorticoid excess on the gonadotropic and somatotropic axes in normal men. J Clin Endocrinol Metab 1992;74:96–102.
2.
Magiakou MA, Mastorakos G, Gomez MT, Rose SR, Chrousos GP: Suppressed spontaneous and stimulated growth hormone secretion in patients with Cushing’s disease before and after surgical cure. J Clin Endocrinol Metab 1994;78:131–137.
3.
Kaji H, Kishimoto M, Kirimura T, Iguchi G, Murata M, Yoshioka S, Iida K, Okimura Y, Yoshimoto Y, Chihara K: Hormonal regulation of the human ghrelin receptor gene transcription. Biochem Biophys Res Commun 2001;284:660–666.
4.
Giustina A, Girelli A, Doga M, Bodini C, Bossoni S, Romanelli G, Wehrenberg WB: Pyridostigmine blocks the inhibitory effect of glucocorticoid on growth hormone-releasing hormone stimulated growth hormone secretion in normal man. J Clin Endocrinol Metab 1990;71:580–584.
5.
Leal-Cerro A, Jimenez LM, Astorga R, Fernandez-Lopez I, Dieguez C, Casanueva FF: Acute pharmacological reduction of plasma free fatty acids enhances the growth hormone (GH)-releasing hormone-mediated GH secretion in patients with Cushing’s syndrome. J Clin Endocrinol Metab 1997;82:3165–3168.
6.
Borges MH, Pinto AC, DiNinno FB, Camacho-Hubner C, Grossman A, Kater CE, Lengyel AM: IGF-1 levels rise and GH responses to GHRH decrease during long-term prednisone treatment in man. J Endocrinol Invest 1999;22:12–17.
7.
Leal-Cerro A, Venegas E, Garcia-Pesquera F, Jimenez LM, Astorga R, Casanueva FF, Dieguez C: Enhanced growth hormone (GH) responsiveness to GH-releasing hormone after dietary restriction in patients with Cushing’s syndrome. Clin Endocrinol (Oxf) 1998;48:117–121.
8.
Heinrichs C, Yanovski JA, Roth AH, et al: Dexamethasone increases growth hormone receptor messenger ribonucleic acid levels in liver and growth plate. Endocrinology 1994;135:1113–1118.
9.
Jux C, Leiber K, Hugel U, Blum W, Ohlsson C, Klaus G, Mehls O: Dexamethasone impairs growth hormone (GH)-stimulated growth by suppression of local insulin-like growth factor (IGF)-1 production and expression of GH- and IGF-1-receptor in cultured rat chondrocytes. Endocrinology 1998;139:3296–3305.
10.
Vottero A, Kimchi-Sarfaty C, Kratzsch J, Chrousos GP, Hochberg Z: Transcriptional and translational regulation of the splicing isoforms of the growth hormone receptor by glucocorticoids. Horm Metab Res, in press.
11.
Bergad PL, Towle HC, Berry SA: Yin-yang 1 and glucocorticoid receptor participate in the Stat5-mediated growth hormone response of the serine protease inhibitor 2.1 gene. J Biol Chem 2000;275:8114–8120.
12.
Martinelli CE Jr, Yateman ME, Cotterill AM, Moreira AC, Camacho-Hubner C: Correlation between cortisol and insulin-like growth factor-binding proteins under physiological conditions in children. Clin Endocrinol (Oxf) 1999;50:767–774.
13.
Skjaerbaek C, Frystyk J, Grofte T, Flyvbjerg A, Lewitt MS, Baxter RC, Orskov H: Serum-free insulin-like growth factor-1 is dose-dependently decreased by methylprednisolone and related to body weight changes in rats. Growth Horm IGF Res 1999;9:74–80.
14.
Beauloye V, Ketelslegers JM, Moreau B, Thissen JP: Dexamethasone inhibits both growth hormone (GH)-induction of insulin-like growth factor-1 (IGF-1) mRNA and GH receptor (GHR) mRNA levels in rat primary cultured hepatocytes. Growth Horm IGF Res 1999;9:205–211.
15.
Maccario M, Tassone F, Gauna C, Oleandri SE, Aimaretti G, Procopio M, Grottoli S, Pflaum CD, Strasburger CJ, Ghigo E: Effects of short-term administration of low-dose rhGH on IGF-1 levels in obesity and Cushing’s syndrome: Indirect evaluation of sensitivity to GH. Eur J Endocrinol 2001;144:251–256.
16.
De Los Rios P, Hill DJ: Expression and release of insulin-like growth factor binding proteins in isolated epiphyseal growth plate chondrocytes from the ovine fetus. J Cell Physiol 2000;183:172–181.
17.
Koedam JA, Hoogerbrugge CM, Van Buul-Offers SC: Differential regulation of IGF-binding proteins in rabbit costal chondrocytes by IGF-1 and dexamethasone. J Endocrinol 2000;165:557–567.
18.
Chevalley T, Strong DD, Mohan S, Baylink D, Linkhart TA: Evidence for a role for insulin-like growth factor binding proteins in glucocorticoid inhibition of normal human osteoblast-like cell proliferation. Eur J Endocrinol 1996;134:591–601.
19.
Gabbitas B, Pash JM, Delany AM, Canalis E: Cortisol inhibits the synthesis of insulin-like growth factor-binding protein-5 in bone cell cultures by transcriptional mechanisms. J Biol Chem 1996;271:9033–9038.
20.
Conover CA, Lee PD, Riggs BL, Powell DR: Insulin-like growth factor-binding protein-1 expression in cultured human bone cells: Regulation by insulin and glucocorticoid. Endocrinology 1996;137:3295–3301.
21.
Hansson A, Hehenberger K, Thoren M: Long-term treatment of Swiss 3T3 fibroblasts with dexamethasone attenuates MAP kinase activation induced by insulin-like growth factor-1. Cell Biochem Funct 1996;14:121–129.
22.
Hochberg Z: Clinical physiology and pathology of the growth plate. Baillières Clin Endocrinol Metab, in press.
23.
Silberman M, Maor G: Mechanism of glucocorticoid induced growth retardation: impairment of cartilage mineralization. Acta Anat 1978;101:140–149.
24.
Hahn TJ, Halstead LT, Teitelbaum SL, et al:. Altered mineral metabolism in glucocorticoid induced osteopenia: Effect of 25-hydroxyvitamin D administration. J Clin Invest 1979;64:655–665.
25.
Zhang W, Watson CE, Liu C, Williams KJ, Werth VP: Glucocorticoids induce a near-total suppression of hyaluronan synthase mRNA in dermal fibroblasts and in osteoblasts: A molecular mechanism contributing to organ atrophy. Biochem J 2000;349:91–97.
26.
Pereira RM, Delany AM, Canalis E: Cortisol inhibits the differentiation and apoptosis of osteoblasts in culture. Bone 2001;28:484–490.
27.
Altman A, Hochberg Z, Silbermann M: Interactions between growth hormone and dexamethasone in skeletal growth and bone structure of the young mouse. Calcif Tissue Int 1992;51:298–304.
28.
Singleton JR, Baker BL, Thorburn A: Dexamethasone inhibits insulin-like growth factor signaling and potentiates myoblast apoptosis. Endocrinology 2000;141:2945–2950.
29.
Chrysis D, Underwood LE: Regulation of components of the ubiquitin system by insulin-like growth factor 1 and growth hormone in skeletal muscle of rats made catabolic with dexamethasone. Endocrinology 1999;140:5635–5641.
30.
Kato Y, Shimazu A, Iwamoto M, Nakashima K, Koike T, Suzuki F, Nishii Y, Sato K: Role of 1,25-dihydroxycholecalciferol in growth-plate cartilage: Inhibition of terminal differentiation of chondrocytes in vitro and in vivo. Proc Natl Acad Sci USA 1990;87:6522–6526.
31.
Inao A, Conrad HE: Coordinate inhibition of alkaline phosphatase and type X collagen synthesis by 1,25-dihydroxyvitamin D3 in primary cultured hypertrophic chondrocytes. Calcif Tissue Int 1992;50:445–450.
32.
Colette C, Monnier L, Pares Herbute N, Blotman F, Mirouze J: Calcium absorption in corticoid-treated subjects effects of a single oral dose of calcitriol. Horm Metab Res 1987;19:335–338.
33.
Vardi P, Benderly A, Etzioni A, Levi J, Hochberg Z: Hypocalcemia induced by glucocorticoids in a child with hypoparathyroidism treated with 1α-hydroxyvitamin D3. Eur J Pediatr 1985;144:280–282.
34.
Nielsen HK, Thomsen K, Eriksen EF, Charles P, Storm T, Mosekilde L: The effects of high-dose glucocorticoid administration on serum bone γ-carboxyglutamic acid-containing protein, serum alkaline phosphatase and vitamin D metabolites in normal subjects. Bone Miner 1988;4:105–113.
35.
Gram J, Junker P, Nielsen HK, Bollerslev J: Effects of short-term treatment with prednisolone and calcitriol on bone and mineral metabolism in normal men. Bone 1998;23:297–302.
36.
LoCascio V, Ballanti P, Milani S, Bertoldo F, LoCascio C, Zanolin EM, Bonucci E: A histomorphometric long-term longitudinal study of trabecular bone loss in glucocorticoid-treated patients: Prednisone versus deflazacort. Calcif Tissue Int 1998;62:199–204.
37.
Ferraris JR, Pasqualini T, Legal S, Sorroche P, Galich AM, Pennisi P, Domene H, Jasper H: Effect of deflazacort versus methylprednisone on growth, body composition, lipid profile and bone mass after renal transplantation. The Deflazacort Study Group. Pediatr Nephrol 2000;14:682–688.
38.
Allen DB, Julius JR, Breen TJ, Attie KM: Treatment of glucocorticoid-induced growth suppression with growth hormone. National Cooperative Growth Study. J Clin Endocrinol Metab 1998;83:2824–2829.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.